J&J Withdraws Power Morcellators
Johnson & Johnson is withdrawing its laparoscopic power morcellators from hospitals amid concerns that the devices may potentially spread undetected uterine sarcoma during fibroid removal and hysterectomy, the Wall Street Journal reports.
Why Johnson & Johnson (JNJ) Stock Is Lower Today
The company plans to tell customers world-wide in a letter today to return the devices known as laparoscopic power morcellators, the Journal said, STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.
National Public Radio
Senate Antitrust Panel Eyes Contact Lens Pricing Policies
Under "UPP," or universal pricing policies, manufacturers like Johnson & Johnson tell retailers they can't sell their contact lens below a certain price.
Wed Jul 30, 2014
The Washington Post
J&J Pulls From Market Hysterectomy Device Tied to Cancer Spread
Johnson & Johnson is pulling from the global market a device used during hysterectomies and other uterine procedures after reports that it may spread and accelerate the growth of undetected cancer inside women.
Mon Jul 28, 2014
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .
Thu Jul 24, 2014
Johnson & Johnson partners with Organovo to consider 3D-printing living tissue
The partnership centers around using bioprinted tissue to discover new drugs. The announcement comes ahead of Organovo's commercial launch later this year.
Wed Jul 23, 2014
The New Zealand Herald
What's best for baby?
Sharon Dowling, research and development manager for leading company Johnson & Johnson , shares her advice.
Mon Jul 21, 2014
Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend
The quarterly dividend is in line with the company's previous. The dividend is payable on Sept.
Wed Jul 16, 2014
Johnson & Johnson Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Wednesday.
J&J's Strong 2Q Led by Pharmaceuticals
Johnson & Johnson reported strong second-quarter results that exceeded both our and consensus expectations largely because of stronger-than-expected pharmaceutical sales.
Tue Jul 15, 2014
Johnson & Johnson Beats on EPS but Sags on a Technical Basis
The large-cap pharmaceutical company also beat on revenue and raised full-year guidance.
Tues., July 15: Hewlett-Packard Among Stocks to Watch
WSJ's Polya Lesova joins Simon Constable on the News Hub to discuss why investors are eyeing Hewlett-Packard, Reynolds American and Johnson & Johnson stock.
J&J Second Quarter Profit Climbs 13%
Johnson & Johnson has reported earnings that climbed by 13 percent in its second quarter, and topped analysts' expectations.
Mon Jul 14, 2014
The Motley Fool
Earnings Preview: Abbott Laboratories and Johnson & Johnson
The health care sector in general, and biotech industry in particular, have now shrugged off their earlier first quarter dip.
Johnson & Johnson (JNJ) to Release Earnings on Tuesday
Johnson & Johnson is set to release its Q214 earnings data on Tuesday, July 15th.
Fri Jul 11, 2014
The Motley Fool
Today's Top Biotech Stocks to Watch: Johnson & Johnson and Sarepta Therapeutics
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Johnson & Johnson ( Analysts are optimistic about Johnson & Johnson's second quarter earnings With J&J set to reveal second quarter earnings next Tuesday, July 15, Wall Street analysts are predicting that the company will beat consensus earnings per share of ... (more)
Wed Jul 09, 2014
The Motley Fool
Is Pharmacyclics the Next Celgene?
Revlimid notched label expansions for use in multiple myeloma in 2006 and mantle cell lymphoma in 2013.
Mon Jul 07, 2014
The Motley Fool
The Dow Breaks Its Streak but Holds 17,000 as Johnson & Johnson and AT&T Rise
Yet even as nervous investors took profits after weighing the potential for future gains against the risk involved in the stock market, the Dow still managed to hang onto the 17,000 level.
Thu Jul 03, 2014
Johnson & Johnson Unit DePuy Synthes Whacks 400 Jobs As Part Of Reorganization
Johnson & Johnson is axing jobs but others are hiring too! Check it out! Faced with an array of challenges, the DePuy Synthes medical device unit of Johnson & Johnson JNJ -0.01% is undergoing a reorganization that will eliminate approximately 400 jobs, or less than 2% of the global DePuy workforce of 23,000 employees.
The Jersey Journal
Family of man found dead in New Brunswick raises money for funeral
OLD BRIDGE - The family of township resident Marcin Gadkowski, who was found dead near the New Brunswick train station on Monday, is raising money for his funeral.